Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
February 2025
The global epidermal growth factors (EGFs) market size is calculated at USD 1.24 billion in 2025 and is forecasted to reach around USD 1.72 billion by 2034, accelerating at a CAGR of 3.75% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global epidermal growth factors (EGFs) market size accounted for USD 1.19 billion in 2024 and is predicted to increase from USD 1.24 billion in 2025 to approximately USD 1.72 billion by 2034, expanding at a CAGR of 3.75% from 2025 to 2034. The increased demand for advanced skincare products, wound healing treatments, and regenerative medicines is driving the global market. The growing innovations in personalized skincare solutions are further contributing to the market growth. The increased demand for advanced skincare products.
Artificial Intelligence is being transformative tool for epidermal growth factors, especially in the analysis and interpretation of human epidermal growth factor receptor 2 (HER2). An AI algorithm is significant for analyzing the epidermal growth factor expression and predicting treatment response. The rising innovations in cancer diagnostics and treatments are driving the adoption of AI technology. The use of AI has increased in the prediction of EGFR mutation from various medical images to guide personalized treatments for lung cancer. AI-driven image analysis and assessments help to reduce variability and enhance the accuracy of treatments. Additionally, the growing awareness of plant-based EGFs is further increasing the shift toward the adoption of AI technology.
The epidermal growth factors (EGFs) market comprises natural and recombinant EGF proteins (human EGF and analogues), and their downstream formulations and applications. EGFs are biologically active peptides that stimulate cell proliferation, migration, and differentiation, used across wound healing & regenerative medicine, dermatology & anti-aging cosmetics, cell-culture/media supplementation, and select therapeutic development programs. Market activity includes reagent/API manufacturing (research- and GMP-grade), finished topical/injectable formulations, and contract manufacturing for clinical programs.
The ongoing innovations and developments of epidermal growth factors for various treatments and applications are the key factors fostering the adoption. The expanding healthcare industry and biopharmaceutical & biotechnology are driving these innovations and developments. Additionally, the surge toward innovative cancer treatments and advanced cosmetic and skincare products is driving the need for epidermal growth factors. Regulatory support for process and approvals for new products and companies' investments in research capacities are bringing significant innovations and growth in the emerging market.
| Report Coverage | Details |
| Market Size by 2034 | USD 1.72 Billion |
| Market Size in 2025 | USD 1.24 Billion |
| Market Size in 2024 | USD 1.19 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 3.75% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Product/Grade, Application/End Use, Formulation/Delivery, End-User/Buyer, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Increased Demand for Anti-Aging Products
The growing aging population, awareness about skin health, and demand for advanced skincare products are driving demand for epidermal growth factors. The rapid surge toward skin rejuvenation and anti-aging products is driving innovations and developments of epidermal growth factors, driven by their stimulation of cell regeneration and repair properties. Epidermal growth factors offer active ingredients that help to rejuvenate and repair skin. The expanding beauty and personal care industry and increasing skin health concerns across the aging population are fostering demand for epidermal growth factors.
Regulatory Challenges
The strict regulatory requirements for epidermal growth factor approvals due to her potential side effects and demand for extensive preclinical and clinical testing to ensure their safety and efficacy are the major hinders for the market growth. The regulatory requirements can lead to product launches and an increased cost burden to manufacturers. The high cost of epidermal growth factors associated with the production and approval process causes barriers for small-scale companies. The regulatory compliance is causing challenges for the development and commercialization of EGF-based products.
Increasing Use in Cancer Therapies
The use of epidermal growth factors is increasing for cancer therapies and treatment solutions, holding significant opportunities for market growth. The increased prevalence of cancer across the globe is driving demand for targeted therapies like EGFR-based treatments. The epidermal growth factors (EGFs) improve epithelial cell growth and accelerate wound healing. The epidermal growth factor receptor (EGFR) signals the pathway malfunction, which leads for contributes to cancer development and progression. The growing use of epidermal growth factors in applications like oncology and regenerative medicine is driving significant innovative approaches in the market growth.
Which Product/Grade Segment Dominated the Epidermal Growth Factors (EGFs) Market in 2024?
In 2024, the recombinant human EGF (rhEGF) segment dominated the market, due to its high use in advanced biotechnological methods to ensure efficacy and purity. The recombinant human EGF (rhEGF) research grade is widely used in basic research and the development of novel therapies. The growing research and development of epidermal growth factors (EGFs) is driving the adoption of recombinant human EGF (rhEGF) research grade for the study of cell differentiation, growth, and tissue repair. The rising use of this grade in various applications like anti-aging treatments, cancer therapies, and wound healing is driving demand for epidermal growth factors (EGFs) in the market.
The GMP/clinical-grade EGF segment is expected to lead the market over the forecast period, due to its increased use in clinical trials and the development of pharmaceutical formulations. The strict regulatory requirements of ensuring safety and efficacy, driving the adoption of GMP/clinical-grade EGF for clinical applications. The demand for GMP-compliant products has increased in cell and gene therapies. Additionally, the growing advancements in biotechnology are enabling high-quality GMP/clinical-grade EGF production, contributing to the segment’s growth.
Which Application/End-use Segment Leads the Epidermal Growth Factors (EGFs) Market?
The dermatology & cosmeceuticals segment led the market in 2024, due to increased awareness about EGFs and their advantages to promote healthy skin and combat signs of aging. The use of epidermal growth factors (EGFs) is widespread in anti-aging products, helping to reduce wrinkles, enhance skin texture, and improve overall skin appearance. Epidermal growth factors (EGFs) play a key role in stimulating cell growth and collagen production. The popularity of EGF-based creams, serums, and mesotherapy treatments is rising in the global market.
The wound care & regenerative medicine segment is the second-largest segment, leading the market, due to the increasing prevalence of chronic wounds, diabetes ulcers, and burn incidences. The epidermal growth factors (EGFs) play a crucial role in tissue regeneration and healing, which is central in stem cell therapies, organ repair, and tissue engineering. The chronic wounds, like diabetic foot ulcers and burns, are key applications that drive demand for epidermal growth factors (EGFs).
What Made Topical/gel/Creams/Serums Dominate the Epidermal Growth Factors in 2024?
The topical gels/creams/serums segment dominated the market in 2024, due to increased adoption of epidermal growth factors (EGFs)-based topical gels/creams/serums for wound care and cosmetic applications. The easy-to-use to use nature and widespread availability of these formulations contribute to increased demand. The topical gels/creams/serums can deliver epidermal growth factors (EGFs) directly to targeted areas. The ability of topical gels/creams/serums to deliver high-concentration EGFs makes them ideal for anti-aging applications. Wound healing, diabetic foot ulcers, and radiation are also the key applications that drive demand for EGF-based topical gels/creams/serums
The injectable/implantable formulations segment is the fastest-growing segment in the market, driven by the rising use of EGF-based injectable/implantable formulations in clinical settings. The injectable and implantable formulations of EGFs provide high bioavailability and effectiveness. Patients with acute wounds need injectable and implantable formulations of epidermal growth factors. The widespread use of these formulations in preclinical and clinical settings is driving the segment.
How Research Labs/Academic Institutes/CROs Segment Dominates the Epidermal Growth Factors Segment in 2024?
In 2024, the research labs/academic institutes/CROs segment dominated the market, due to increased research and development of epidermal growth factors. The research labs, academic institutes, and CROs drive the adoption of epidermal growth factors for various applications such as fundamental research, preclinical studies, and drug development. The growing emphasis of research labs/academic institutes to enhance scientific understanding of EGFs and their role in biological processes is fostering the demand. Additionally, the key role of CROs in supporting pharmaceutical and biotechnology companies is contributing to the segment’s growth.
The biotech/pharma firms (clinical developers) segment is expected to lead the market over the forecast period, due to rising adoption of epidermal growth factors in key areas like wound healing and cancer therapies. The biotech/pharma firms are investing heavily in formulation, delivery systems, and combination therapies for cancer by using epidermal growth factors. The growing investments in EGF-based research for the development of novel applications and strategic partnerships with research and academic institutions are contributing to the biotech/pharma firms segment.
North America Epidermal Growth Factors (EGFs) Market
North America dominates the global epidermal growth factors (EGFs) market, driven by the region’s strong pharmaceutical expenditure and robust biotechnology sector. North America has an advanced healthcare infrastructure that drives a strong emphasis on clinical research, trials, and the adoption of novel therapies. Strong investments in research and development and growing applications in biopharmaceutical and biotechnology companies are fostering the adoption of EGFs. Additionally, the growing demand for anti-aging products in various regional countries is contributing to the market growth.
The U.S. is a major player in the regional market, contributing to the growth due to the strong existence of key market companies and robust research and development infrastructure. The growing geriatric populations and awareness about skin health have boosted significant innovations in epidermal growth factors in U.S. research institutions. Additionally, the growing number of cancers and efforts in the development of novel and innovative treatments are further contributing to the market expansion.
Asia Pacific Epidermal Growth Factors (EGFs)
Asia Pacific is the fastest-growing region in the global market, contributing to growth due to a growing geriatric population, increasing demand for advanced skincare products, and growing advancements in biotechnology. Countries like China, India, and Japan are leading the regional biotechnology sector, driving significant approaches of innovations and developments of epidermal growth factors (EGFs) for various applications and treatments. Additionally, strategic investments and acquisitions by key market players are further driving innovation of the epidermal growth factors (EGFs).
China and South Korea are leading the regional market, due to the countries' significant advancements in biotechnology infrastructure and the trend of C-beauty and K-beauty. The demand for epidermal growth factors (EGFs) is high in China’s and South Korea’s healthcare and cosmetic sectors. The growing awareness about regenerative therapies and skincare products.
In June 2025, a clinical-stage biotechnology company developing next-generation oncology therapies, Avenzo Therapeutics, Inc., collaborated with Duality Biotechnology for entering into an exclusive license agreement for the development, manufacturing, and commercialization of AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC, in the global market, particularly in China. (Source: https://biopharmaapac.com)
Europe Epidermal Growth Factors (EGFs) Market
Europe is a notable player in the regional market, driven by countries' robust R&D infrastructure and advanced healthcare sector. Europe has experienced significant demand for epidermal growth factors (EGFs) in skincare and oncology applications. The growing innovations and developments of novel oncology treatments and therapies are fostering the use of epidermal growth factors (EGFs). Additionally, the strong existence of strict regulations like the European Medicines Agency (EMA) streamlines biological approvals for epidermal growth factors (EGFs), fueling the market acceptance and availability.
Germany is a major player in the regional market, contributing to growth due to the country's strong biopharmaceutical & biotechnology companies and strong research and development sector. The strong government support in research & development and expanding healthcare expenditure, boosting the market. The regenerative medicine and personalized skincare segments are dominating the German epidermal growth factors (EGFs) market.
By Product / Grade
By Application / End Use
By Formulation / Delivery
By End-User / Buyer
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
February 2025
June 2025
November 2024
July 2025